A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ALCHEMIST) (E4512)

This study is for the treatment of non-small cell lung cancer.

Study phase: III

Primary disease category: Cancer

Secondary disease categories: Cancer, Lung Cancer

Protocol number: E4512

Projected enrollment dates: October 2015 to May 2022

Official study title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ALCHEMIST) (E4512)

ClinicalTrials.gov page:
http://www.clinicaltrials.gov/show/NCT02201992

You are here

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ALCHEMIST) (E4512)